Ioannis Theodorakos1, Georgios Paterakis1, Vassilios Papadakis2, Ales Vicha3, Georgios Topakas1, Pavla Jencova3, Eirini Karchilaki1, Anna Taparkou4, Nikolaos J Tsagarakis1, Sophia Polychronopoulou2. 1. Flow Cytometry Laboratory, Department of Immunology, Athens Regional General Hospital "G. Gennimatas,", Athens, Greece. 2. Department of Pediatric Hematology-Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece. 3. Department of Pediatric Hematology and Oncology, Charles University, 2nd Faculty of Medicine and Faculty Hospital Motol, Prague, Czech Republic. 4. 1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
Abstract
BACKGROUND: Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45- /CD56+ ) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. PROCEDURE: RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. RESULTS: The frequency of RCP in B-ALL BM samples was < 1/1 × 104 cells (bulky lysis), and their immunophenotypic profile was indicative of CD56+ mesenchymal stromal cells (MSCs) (CD45- , CD90+ , CD146+ , CD73+ ). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56+ MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. CONCLUSIONS: RCP that were immunophenotypically similar to NBL were identified as CD56+ MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.
BACKGROUND: Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45- /CD56+ ) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. PROCEDURE: RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. RESULTS: The frequency of RCP in B-ALL BM samples was < 1/1 × 104 cells (bulky lysis), and their immunophenotypic profile was indicative of CD56+ mesenchymal stromal cells (MSCs) (CD45- , CD90+ , CD146+ , CD73+ ). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56+ MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. CONCLUSIONS: RCP that were immunophenotypically similar to NBL were identified as CD56+ MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.
Authors: Sabine Heitzeneder; Kristopher R Bosse; Zhongyu Zhu; Doncho Zhelev; Robbie G Majzner; Molly T Radosevich; Shaurya Dhingra; Elena Sotillo; Samantha Buongervino; Guillem Pascual-Pasto; Emily Garrigan; Peng Xu; Jing Huang; Benjamin Salzer; Alberto Delaidelli; Swetha Raman; Hong Cui; Benjamin Martinez; Scott J Bornheimer; Bita Sahaf; Anya Alag; Irfete S Fetahu; Martin Hasselblatt; Kevin R Parker; Hima Anbunathan; Jennifer Hwang; Min Huang; Kathleen Sakamoto; Norman J Lacayo; Dorota D Klysz; Johanna Theruvath; José G Vilches-Moure; Ansuman T Satpathy; Howard Y Chang; Manfred Lehner; Sabine Taschner-Mandl; Jean-Phillipe Julien; Poul H Sorensen; Dimiter S Dimitrov; John M Maris; Crystal L Mackall Journal: Cancer Cell Date: 2021-12-30 Impact factor: 38.585
Authors: K O McNerney; S Karageorgos; G M Ferry; A J Wolpaw; C Burudpakdee; P Khurana; C N Toland; R Vemu; A Vu; M D Hogarty; H Bassiri Journal: Oncoimmunology Date: 2022-05-24 Impact factor: 7.723
Authors: Amos H P Loh; Clara Angelina; Meng Kang Wong; Sheng Hui Tan; Sarvesh A Sukhatme; Trifanny Yeo; Su Bin Lim; York Tien Lee; Shui Yen Soh; Wing Leung; Kenneth T E Chang; Yong Wei Chua; Syed M F Alkaff; Tony K H Lim; Chwee Teck Lim; Zhi Xiong Chen Journal: Front Oncol Date: 2022-09-13 Impact factor: 5.738